Professor Gerald R. Fink, Ph.D., Former Director of the Whitehead Institute/MIT, to Join Dyadic Scientific Advisory Board.

Business Editors/Health/Medical Writers

BIOWIRE2K

JUPITER, Fla.--(BUSINESS WIRE)--May 13, 2004

Dyadic International, Inc., a leading biotechnology company that is focused on providing innovative products and solutions based on its protein expression technology to a wide range of industries, announced today that Dr. Gerald R. Fink, American Cancer Society Professor at the Whitehead Institute/Massachusetts Institute of Technology (MIT), founding Member and former Director of the Whitehead Institute/MIT, has joined the company's Scientific Advisory Board.

"We are delighted to add Dr. Fink to the Dyadic scientific team," said Mark Emalfarb, President and CEO of Dyadic. "His scientific expertise specifically relates to our ongoing research efforts to turn complex genes into proteins using our C1 protein expression system. Gerry's vast experience in our field as well as his broad scientific and industry network will be invaluable to Dyadic as we continue to develop our technology to become the gold standard protein expression system for applications in biopharmaceutical and other markets."

"Gerry is truly a great scientist with specific expertise in fungal expression," added Dr. Richard Lerner, the Chairman of Dyadic's Scientific Advisory Board. "I have worked with him for a long time on a variety of scientific pursuits and we know first hand that important things happen when you link together brilliant scientists with great technologies."

"Dyadic is a leader in the production of key proteins from fungi," commented Dr. Fink. "I am enthusiastic about helping the company mine this rich source of proteins, which are so important for industry and medicine."

Dr. Fink is a founding Member of the Whitehead Institute and American Cancer Society Professor of Genetics at MIT. He served as Director of the Whitehead Institute from 1990 to 2001. Dr. Fink received his Ph.D. in genetics from Yale University, conducted postdoctoral research at the National Institutes of Health and served for 15 years on the faculty of Cornell University. He is a past President of the Genetics Society of America, a Member of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, a Member of the Institute of Medicine, a Member of the Medical Advisory Board of the Howard Hughes Medical Institute and a non-resident Member of the Salk Institute. Among his many honors and awards are the National Academy of Sciences/U.S. Steel Foundation Award in Molecular Biology, the Medal of the Genetics Society of America, the Hansen Foundation Award for Microbiological Research and the Yale Science and Engineering Award. He received the first honorary doctorate awarded by Cold Spring Harbor Laboratory in 1999.

Dr. Fink is a world renowned expert in the field of molecular genetics and cell biology of brewers' yeast and Candida. He leads research into common baker's yeast to explore critical pathways in cell growth and metabolism. The applications of this research include cancer research and the development of new anti-fungal drugs.

The Whitehead Institute (http://www.whitehead.mit.edu) is a non-profit, independent research and teaching institution recognized worldwide for leading edge programs in genomics, cell biology, cancer research, structural biology, and infectious disease. The Whitehead Institute is affiliated with the Massachusetts Institute of Technology in its teaching activities, but is wholly responsible for its own research programs, governance, and finance.

About Dyadic

Dyadic International, Inc. is a private biotechnology company. Dyadic has been executing its business plan by leveraging the considerable know-how, relationships, and cash flow from its industrial enzyme business to develop its patented C1 gene discovery and expression platform technology. Dyadic's Gene Discovery technology uses state-of-the-art robotic screening to identify and evolve therapeutically relevant genes. Dyadic's Gene Expression system converts those genes into their protein products. Finally, utilizing its Product Development expertise and Large-scale Manufacturing know-how and alliances, Dyadic brings those products to market economically. All of the above technologies use a single biological host, Dyadic's proprietary C1 fungal host system. The integrated platform provides a total package for bringing products from discovery to commercialization. Using this integrated technology platform also increases the odds of R&D success while shortening the timeline for new product and process development. Dyadic is using its proprietary technologies to discover, develop and manufacture commercial quantities of protein products and enzymes for applications in the pharmaceutical, biotechnology, textile, chemical, agricultural, pulp & paper and other industries.